Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- TU
- CU
Lists including David
Investments
Work Experience
2018
General Partner
2019
Venture Partner
2018 - 2019
2021
Chairman, Founding CEO
2021
2022
Board Member, Founding CEO
2022
2021
Board Member
2021
2020
Chairman, Founding CEO
2020
Be Biopharma (www.be.bio) is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy
2020
Board Member
2020
2019 - 2021
Founding CEO, former Chairman
2019 - 2021
Pyxis Oncology (NASDAQ:PYXS) is developing therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment. www.pyxisoncology.com
2017 - 2020
Co-Founder
2017 - 2020
Targeting the biology of aging to prevent or treat aging-related diseases
2016 - 2018
Founding CEO
2016 - 2018
Vor Biopharma (NASDAQ:VOR) is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.
2011 - 2018
Founding CEO
2011 - 2018
Rationally designing medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies.